KURA Stock — Kura Oncology Inc.: Cash, EV, Pipeline

What they do

We are a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Since our founding in 2014, we have transformed from a research and development company to a fully-integrated commercial-stage organization with a diversified pipeline of product candidates.

Source: 10-K FY2025 via SEC EDGAR

Share price

$7.27

Market cap

$646.7M

Cash

$519.0M

Enterprise value

$133.2M

Balance sheet

Cash	$519.0M
Debt	$5.6M
Net cash	$513.5M
Enterprise value	$133.2M
Basic shares	89.0M shares
Fully diluted shares	110.5M shares
Fully diluted market cap	$803.4M
Cash per share	$5.83
Quarterly burn	$62.5M
Cash runway	8.3 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

89.0M

Pre-funded warrants

0.0M

Options

15.8M

RSUs

3.0M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

2.7M

FDSO

110.5M

Cap table as of 2026-06-30.

Price history

Loading KURA daily closes…

Loading price history…

Next catalyst

Ziftomenib · Jan 12 - Feb 23 in 9 wks · Phase 1 · AML; AML With Mutated NPM1; Hematologic Malignancy

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jan 12 - Feb 23 in 9 wks	Ziftomenib	Phase 1	AML; AML With Mutated NPM1; Hematologic Malignancy	—
Feb 12 - Mar 26 in 14 wks	Darlifarnib	Phase 1	Solid Tumors With HRAS Alterations; Non Small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC)	—
Jan 12 - Feb 23 in 14 mo	ziftomenib	Phase 1	Gastrointestinal Stromal Tumor (GIST); Gastrointestinal Stromal Cancer; Gastrointestinal Stromal Neoplasm	—
Nov 27, 2028 - Jan 8, 2029 in 25 mo	Ziftomenib	Phase 2	Advanced Malignant Neoplasm; Acute Myeloid Leukemia; Mixed Lineage Leukemia	—
May 13 - Jun 24 in 43 mo	Ziftomenib	Phase 1	Acute Myeloid Leukemia; Mixed Lineage Leukemia Gene Mutation; Refractory AML	—
Dec 13, 2031 - Jan 24, 2032 in 62 mo	Ziftomenib	Phase 3	Acute Myeloid Leukemia (AML)	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

ziftomenib

Stage not disclosed · Active Modality: small molecule

Aliases ziftomenib

Target menin

Partnerships Kyowa Kirin (exclusive license to develop, manufacture and commercialize ziftomenib outside of the United States; performance obligations for monotherapy and combination development services)

Indications

Acute Myeloid Leukemia (Phase 3)
Acute Myeloid Leukemia (AML) (Phase 3)
Advanced Malignant Neoplasm (Phase 3)

Status note Menin inhibitor (target/modality per 10-K fallback); the primary 10-Q discloses the Kyowa Kirin ex-US license and ziftomenib-related R&D costs. Stage and indications not stated in the primary excerpts.

Per-asset detail extracted from the 10-Q filed 2026-08-03. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Ziftomenib
Lead indication	Acute Myeloid Leukemia (AML)
Lead phase	Phase 3
Active trials	6
Collaborator trials	5

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07007312	Phase 3	Recruiting	Sponsor	KURA	—	Acute Myeloid Leukemia (AML)	—
NCT04067336	Phase 2	Active, not recruiting	Sponsor	KURA	—	Advanced Malignant Neoplasm; Acute Myeloid Leukemia; Mixed Lineage Leukemia	—
NCT06001788	Phase 1	Recruiting	Sponsor	KURA	—	AML; AML With Mutated NPM1; Hematologic Malignancy	—
NCT06026410	Phase 1	Recruiting	Sponsor	KURA	—	Solid Tumors With HRAS Alterations; Non Small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC)	—
NCT06655246	Phase 1	Recruiting	Sponsor	KURA	—	Gastrointestinal Stromal Tumor (GIST); Gastrointestinal Stromal Cancer; Gastrointestinal Stromal Neoplasm	—
NCT05735184	Phase 1	Recruiting	Sponsor	KURA	—	Acute Myeloid Leukemia; Mixed Lineage Leukemia Gene Mutation; Refractory AML	—
NCT06930352	Phase 2	Recruiting	Collaborator	Uma Borate	—	Acute Myeloid Leukemia	—
NCT05848687	Phase 2	Recruiting	Collaborator	Tanja Andrea Gruber	AMGN	Lymphoblastic Leukemia	—
NCT07355335	Phase 1	Not yet recruiting	Collaborator	Massachusetts General Hospital	BMY	KMT2A-rearranged; NPM1-mutant Refractory or Relapsed AML	—
NCT06397027	Phase 1	Recruiting	Collaborator	M.D. Anderson Cancer Center	—	Refractory Acute Leukemia; Pediatric Relapsed	—
NCT06448013	Phase 1	Recruiting	Collaborator	M.D. Anderson Cancer Center	—	Acute Myeloid Leukemia	—

Sponsor-matched active trials from ClinicalTrials.gov (6 as sponsor, 5 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 11 active trials for Kura Oncology, Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
BVF Partners	8,445,769	no change	2.37%	2026-08-14
Sphera Biotech	295,039	-483	0.46%	2026-08-14
Ally Bridge Group	290,000	+290,000	4.10%	2026-08-14
DAFNA Capital	120,568	-115,300	0.25%	2026-08-14
ADAR1 Capital Management	40,000	no change	0.02%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

KURA — Kura Oncology Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

KURA — Kura Oncology Inc.